Diabetes research and clinical practice最新文献

{"title":"Responses to lifestyle interventions among individuals with distinct pre-diabetes phenotypes: A systematic review and Meta-Analysis","authors":"Jincheng Rong,&nbsp;Mandy Ho,&nbsp;Disheng Zhou,&nbsp;Pui Hing Chau","doi":"10.1016/j.diabres.2024.111939","DOIUrl":"10.1016/j.diabres.2024.111939","url":null,"abstract":"<div><h3>Aims</h3><div>To assess responses to lifestyle interventions (LIs) among individuals with distinct pre-diabetes phenotypes (isolated impaired fasting glucose [i-IFG], isolated impaired glucose tolerance [i-IGT], and combined IFG + IGT) for reducing diabetes incidence, reversing pre-diabetes, and improving glycemic control and insulin sensitivity.</div></div><div><h3>Methods</h3><div>PubMed, Embase, Cochrane Library, and Web of Science were searched until December 6th, 2023. We included randomized controlled trials examining responses to LIs (including diet and/or physical activity) among adults with i-IFG, i-IGT, and IFG + IGT. Outcomes included diabetes incidence, normoglycemia incidence, fasting plasma glucose (FPG), 2-hour plasma glucose (2 h-PG), hemoglobin A1c, fasting insulin (FI), and homeostasis model assessment-insulin resistance (HOMA-IR). Random-effects <em>meta</em>-analyses were performed to estimate risk ratios (RRs) and mean differences.</div></div><div><h3>Results</h3><div>Twenty-seven studies were included. Meta-analysis of 10 studies that performed stratified analyses by pre-diabetes phenotype found that LIs significantly reduced diabetes incidence in i-IGT (RR = 0.69 [0.56; 0.85], I² = 14 %) and IFG + IGT (RR = 0.56 [0.48; 0.66], I² = 0 %) but not in i-IFG (RR = 0.85 [0.66; 1.11], I² = 0 %; <em>p</em>_subgroup = 0.02). Meta-analysis of 20 studies using IGT for participant recruitment showed that LIs significantly decreased diabetes incidence, increased normoglycemia incidence, and improved FPG, 2 h-PG, FI and HOMA–IR.</div></div><div><h3>Conclusions</h3><div>LIs are effective for IGT (with or without IFG), but tailored LIs are needed for i-IFG to prevent diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111939"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes specialist nurse support, training and ‘virtual’ advice reduces district nurse visits and improves outcomes for people with diabetes requiring visits for insulin administration","authors":"Laura Gilligan ,&nbsp;Emma Page ,&nbsp;Jo Hall ,&nbsp;Kelly Ward ,&nbsp;William K. Gray ,&nbsp;Tim W.R. Briggs ,&nbsp;Gerry Rayman","doi":"10.1016/j.diabres.2024.111948","DOIUrl":"10.1016/j.diabres.2024.111948","url":null,"abstract":"<div><h3>Aims</h3><div>We evaluated the effectiveness of a community diabetes specialist nurse (cDSN) working with district nurses (DNs) to optimise insulin therapy on DN workload and patient outcomes.</div></div><div><h3>Methods</h3><div>This was an observational clinical improvement study of outcomes pre- and post-introduction of an intervention within a community diabetes service in an areas of England. Patients were followed up for 6 months. The intervention was a cDSN providing advice and support to DNs in safe diabetes management, with a particular focus on insulin use.</div></div><div><h3>Results</h3><div>in total, 148 of 224 patients were reviewed; 130 (87.8 %) were available for follow up 6 months after their first review. Comparing pre- to post-intervention outcomes, number of patients with a hypoglycaemic event reduced from 21/129 to 1/128 (X² = 19.71, p &lt; 0.001) as did the number with a hyperglycaemic event; 53/129 to 23/128 (X² = 16.48, p &lt; 0.001). Number of DN visits and use of acute hospital services also improved significantly. Estimated cost savings through reduced DN visits, insulin usage, and hospital service use totalled £1.9 million.</div></div><div><h3>Conclusions</h3><div>Significant financial savings and reduced patient harms were identified following our intervention in this cohort. Roll-out to other sites in England is a next step.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111948"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease","authors":"Zobair M. Younossi ,&nbsp;J.Michael Estep ,&nbsp;Sean Felix ,&nbsp;Brian Lam ,&nbsp;Zaid Younossi ,&nbsp;Andrei Racila ,&nbsp;Maria Stepanova","doi":"10.1016/j.diabres.2024.111960","DOIUrl":"10.1016/j.diabres.2024.111960","url":null,"abstract":"<div><h3>Background</h3><div>Association of genetic factors with non-invasive tests (NITs) for MASLD has not been well established.</div></div><div><h3>Methods</h3><div>Clinical and laboratory data, liver biopsy and/or liver stiffness measurement (LSM) by transient elastography were collected from MASLD patients seen in tertiary care hepatology practices. Minor allele frequency for genomic loci rs641738 (<em>MBOAT7</em>), rs58542926 (<em>TM6SF2</em>), rs738409 (<em>PNPLA3</em>), rs62305723 (<em>HSD1713B</em>) were evaluated for association with high ELF (≥11.3), high FIB-4 (≥3.25), high LSM (≥10 kPa), histologic fibrosis (stage 3/4 vs. stages 0–2).</div></div><div><h3>Results</h3><div>Among 2289 MASLD patients with available polymorphism and liver fibrosis/NIT data [52 ± 13 years, 46 % male, BMI 36.6 ± 9.9, 35 % type 2 diabetes (T2D)], 53 % had high-risk allele (C &gt; G) at rs738409 (<em>PNPLA3</em>), 70 % high-risk allele (C &gt; T) at rs641738 (<em>MBOAT7</em>), 18 % high-risk minor allele (C &gt; T) at rs58542926 (<em>TM6SF2</em>), 11 % low-risk minor allele (G &gt; A) at rs62305723 (<em>HSD17b13</em>). Only <em>PNPLA3</em>-rs738409 (47 % CC, 40 % CG, 13 % GG) was significantly associated with higher NIT scores and histologic fibrosis: high ELF 2.8 % CC vs. 8.1 % CG/GG; high FIB-4 4.7 % CC vs. 11.6 % CG/GG; high LSM 10 % vs. 19 %; advanced histologic fibrosis 34 % CC vs. 60 % CG/GG (all p &lt; 0.01). Similar associations of <em>PNPLA3</em>-rs738409 with NITs were observed in a subgroup of MASLD patients with T2D (n = 799; all p &lt; 0.05). The <em>PNPLA3</em>-rs738409 CG/GG genotype, older age and T2D were independently associated with high ELF [OR (95 % CI) = 3.25 (2.03–5.20)], FIB-4 [OR = 2.75 (1.90–3.98)], LSM [OR = 2.71 (1.60–4.59)] scores and advanced histologic fibrosis [OR = 2.56 (1.81–3.62)].</div></div><div><h3>Conclusions</h3><div>The polymorphism rs738409 in the <em>PNPLA3</em> gene, T2D, and older age were independent predictors of high-risk MASLD.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111960"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and practitioner perceptions around use of artificial intelligence within the English NHS diabetic eye screening programme","authors":"Charlotte Wahlich ,&nbsp;Lakshmi Chandrasekaran ,&nbsp;Umar A.R. Chaudhry ,&nbsp;Kathryn Willis ,&nbsp;Ryan Chambers ,&nbsp;Louis Bolter ,&nbsp;John Anderson ,&nbsp;Royce Shakespeare ,&nbsp;Abraham Olvera-Barrios ,&nbsp;Jiri Fajtl ,&nbsp;Roshan Welikala ,&nbsp;Sarah Barman ,&nbsp;Catherine A. Egan ,&nbsp;Adnan Tufail ,&nbsp;Christopher G. Owen ,&nbsp;Alicja R. Rudnicka","doi":"10.1016/j.diabres.2024.111964","DOIUrl":"10.1016/j.diabres.2024.111964","url":null,"abstract":"<div><h3>Aims</h3><div>Automated retinal image analysis using Artificial Intelligence (AI) can detect diabetic retinopathy as accurately as human graders, but it is not yet licensed in the NHS Diabetic Eye Screening Programme (DESP) in England. This study aims to assess perceptions of People Living with Diabetes (PLD) and Healthcare Practitioners (HCP) towards AI’s introduction in DESP.</div></div><div><h3>Methods</h3><div>Two online surveys were co-developed with PLD and HCP from a diverse DESP in North East London. Surveys were validated through interviews across three centres and distributed via DESP centres, charities, and the British Association of Retinal Screeners. A coding framework was used to analyse free-text responses.</div></div><div><h3>Results</h3><div>387 (24%) PLD and 98 (37%) HCP provided comments. Themes included trust, workforce impact, the patient-practitioner relationship, AI implementation challenges, and inequalities. Both groups agreed AI in DESP was inevitable, would improve efficiency, and save costs. Concerns included job losses, data security, and AI decision safety. A common misconception was that AI would directly affect patient interactions, though it only processes retinal images.</div></div><div><h3>Conclusions</h3><div>Limited understanding of AI was a barrier to acceptance. Educating diverse PLD groups and HCP about AI’s accuracy and reliability is crucial to building trust and facilitating its integration into screening practices.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111964"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"YKL-40, cardiovascular events, and mortality in individuals recently diagnosed with type 2 diabetes: A Danish cohort study","authors":"Alisa D. Kjaergaard ,&nbsp;Allan Vaag ,&nbsp;Verena H. Jensen ,&nbsp;Michael H. Olsen ,&nbsp;Kurt Højlund ,&nbsp;Peter Vestergaard ,&nbsp;Torben Hansen ,&nbsp;Reimar W. Thomsen ,&nbsp;Niels Jessen","doi":"10.1016/j.diabres.2024.111970","DOIUrl":"10.1016/j.diabres.2024.111970","url":null,"abstract":"<div><h3>Aims</h3><div>We investigated the association of the inflammatory biomarker YKL-40 with cardiovascular events (CVEs) and mortality in individuals with type 2 diabetes.</div></div><div><h3>Methods</h3><div>We followed 11,346 individuals recently diagnosed with type 2 diabetes for up to 14 years. Baseline YKL-40 levels (measured in 9,010 individuals) were grouped into percentiles (0–33 %, 34–66 %, 67–90 %, and 91–100 %) and analyzed continuously (per 1 SD log increment), with comparisons to CRP (measured in 9,644 individuals). Cox regression assessed associations with atrial fibrillation (AF), ischemic stroke (IS), venous thromboembolism (VTE), myocardial infarction (MI), heart failure (HF), peripheral artery disease (PAD), and all-cause, cardiovascular, and cancer mortality.</div></div><div><h3>Results</h3><div>Adjusted HRs (95% CIs) for the highest (91–100%) versus the lowest (0–33%) YKL-40 percentile category were 1.31 (1.04–1.66) for AF, 1.43 (0.98–2.07) for IS, 1.07 (0.65–1.76) VTE, 0.88 (0.52–1.48) for MI, 1.66 (1.19–2.31) for HF, 1.66 (1.12–2.48) for PAD, and 2.18 (1.85–2.56) for all-cause, 1.64 (1.07–2.50) for cardiovascular, and 2.73 (2.05–3.63) for cancer mortality. Each 1 SD log increase in YKL-40 and CRP levels similarly increased CVE risks, with CRP being superior for MI and cardiovascular mortality.</div></div><div><h3>Conclusions</h3><div>YKL-40 is a prognostic biomarker for most CVEs, and even more so for all-cause mortality, primarily driven by cancer-related causes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111970"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world safety of dapagliflozin plus metformin in patients of type 2 diabetes mellitus in China: Post-hoc analysis of the DONATE study","authors":"Lixin Guo ,&nbsp;Jing Wang ,&nbsp;Li Li ,&nbsp;Lin Yuan ,&nbsp;Sheng Chen ,&nbsp;Hui Wang ,&nbsp;Tonghuan Li ,&nbsp;Lin Qi ,&nbsp;Hong Yang","doi":"10.1016/j.diabres.2024.111959","DOIUrl":"10.1016/j.diabres.2024.111959","url":null,"abstract":"<div><h3>Aim</h3><div>DONATE (NCT03156985) is a large-scale real-world study investigating the safety of dapagliflozin in Chinese type 2 diabetes mellitus (T2DM) patients. This post-hoc analysis aims to further evaluate the real-world safety of dapagliflozin plus metformin.</div></div><div><h3>Methods</h3><div>Safety outcomes were assessed in patients receiving concomitant dapagliflozin and metformin, with or without other antidiabetics. The safety of dapagliflozin-based dual-therapies and dapagliflozin and metformin-based triple-therapies were also analysed.</div></div><div><h3>Results</h3><div>Among the 2,990 patients in DONATE, 2,165 (72.4%) received concomitant metformin. Among these 2,165 patients, 780 (36.0%) experienced ≥1 adverse event (AE), 129 (6.0%) experienced serious AE (SAE), and 96 (4.4%) experienced AE leading to dapagliflozin discontinuation. The most common AEs were upper respiratory tract infection (4.0%), urinary tract infection (UTI, 2.1%) and constipation (1.5%). The most common AEs of special interest of dapagliflozin were UTI (2.3%), genital tract infection (1.5%) and hypoglycaemia (1.1%). In the dapagliflozin and metformin dual-therapy subgroup, the incidences of AE, SAE and AE leading to dapagliflozin discontinuation were 26.7%, 2.5%, and 1.9%, respectively, numerically lower than that of the total population and most other dual-therapy subgroups. These patients also had numerically improved metabolic outcomes than baseline.</div></div><div><h3>Conclusion</h3><div>Dapagliflozin and metformin combination therapy is well-tolerated in real-world Chinese T2DM patients.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111959"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in target organ damage in individuals with intermediate hyperglycemia and type 2 diabetes identified by 1-hour plasma glucose during an oral glucose tolerance test","authors":"Chiara Maria Assunta Cefalo ,&nbsp;Alessia Riccio ,&nbsp;Teresa Vanessa Fiorentino ,&nbsp;Elena Succurro ,&nbsp;Gaia Chiara Mannino ,&nbsp;Maria Perticone ,&nbsp;Angela Sciacqua ,&nbsp;Francesco Andreozzi ,&nbsp;Giorgio Sesti","doi":"10.1016/j.diabres.2024.111941","DOIUrl":"10.1016/j.diabres.2024.111941","url":null,"abstract":"<div><div><strong>Aims</strong>: The International Diabetes Federation (IDF) has recently recommended determination of 1-hour glucose during an oral glucose tolerance test (OGTT) to diagnose intermediate hyperglycemia (IH) and type 2 diabetes (T2D). Herein, we investigated the implications of IDF recommendation for characterizing the risk of cardiovascular target organ damage including left ventricular mass normalized by body surface area (LVM index [LVMI]), and myocardial mechano-energetic efficiency normalized by LVM (MEEi) in individuals with IH and T2D. <strong>Methods:</strong> LVMI, and MEEi were assessed in 1847 adults classified on the basis of fasting, 1-hour and 2- hour glucose during an OGTT according to the IDF recommendation as having normal glucose tolerance (NGT, n = 736), isolated impaired fasting glucose (iIFG, n = 105), IH (n = 676), and newly diagnosed T2D (n = 330). <strong>Results:</strong> As compared with NGT group, individuals with either IH or T2D exhibited significantly higher LVMI (97 ± 26, 109 ± 30, and 116 ± g/m2, P &lt; 0.001, respectively), and a decrease in MEEi (0.42 ± 0.11, 0.37 ± 0.10, and 0.35 ± 0.11 ml/sec*g-1, P &lt; 0.001, respectively). LVMI, and MEEi did not differ between NGT and iIFG groups. <strong>Conclusion:</strong> The thresholds of 1-hour post-load glucose proposed by IDF as diagnostic criteria for IH and T2D are capable of detecting individuals at risk of cardiovascular target organ damage.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111941"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conservative surgery for forefoot osteomyelitis may increase reulceration-free survival compared to minor amputation in diabetes-related foot disease","authors":"Gerardo Víquez-Molina ,&nbsp;José María Rojas-Bonilla ,&nbsp;Javier Aragón-Sánchez","doi":"10.1016/j.diabres.2024.111949","DOIUrl":"10.1016/j.diabres.2024.111949","url":null,"abstract":"<div><div>This study suggests that conservative surgery may improve reulceration-free survival in patients with diabetes-related forefoot osteomyelitis, compared to minor amputation. By excluding patients with prior surgeries, the analysis more accurately reflects the benefits of conservative surgery. These findings highlight the importance of preserving foot structure to maintain biomechanics and reduce reulceration risk.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111949"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WeChat mini-program, a preliminary applied study of the gestational blood glucose management model for pregnant women with gestational diabetes mellitus","authors":"Qiaosong Wang ,&nbsp;Kun Zhang ,&nbsp;Xueling Zhang ,&nbsp;Jie Fu ,&nbsp;Fangyi Liu ,&nbsp;Yinge Gao ,&nbsp;Rongjin Lin","doi":"10.1016/j.diabres.2024.111943","DOIUrl":"10.1016/j.diabres.2024.111943","url":null,"abstract":"<div><h3>Background</h3><div>The mHealth has been increasing in pregnancy. However, the WeChat mini-program based gestational glucose management model for gestational diabetes mellitus (GDM) during pregnancy has not been established.</div></div><div><h3>Methods</h3><div>56 GDM pregnant women were selected. The control group received routine pregnancy health care, and the experimental group received WeChat mini-program GDM women’s blood glucose management model, Intervention from diagnosis of GDM to delivery. Two-hour postprandial glucose, self-management ability, maternal and infant outcomes, satisfaction and so on were collected, with an additional mHealth app usability questionnaire collected by the experimental group.</div></div><div><h3>Results</h3><div>The WeChat mini-program GDM women’s blood glucose management model reduced two-hour postprandial glucose, the birth weight of newborns and the incidence of other complications(P &lt; 0.05). The model also improved self-management ability and blood glucose management satisfaction(P &lt; 0.01). The mHealth app usability questionnaire score tends to be close to 1, which indicates that the WeChat mini-program has usability.</div></div><div><h3>Conclusion</h3><div>The WeChat mini-program blood glucose management model reduces two-hour postprandial glucose and improves the self-management ability, which verifies the feasibility and effectiveness of the blood glucose management model relying on the WeChat mini-program.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111943"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body roundness index as a predictor of all-cause and cardiovascular mortality in patients with diabetes and prediabetes","authors":"Peipei Wang ,&nbsp;Yongqiang Fan ,&nbsp;Haoyue Gao ,&nbsp;Bei Wang","doi":"10.1016/j.diabres.2024.111958","DOIUrl":"10.1016/j.diabres.2024.111958","url":null,"abstract":"<div><h3>Background</h3><div>There are limited population-based studies examining the correlation between body roundness index (BRI) and mortality in diabetes and prediabetes patients.</div></div><div><h3>Method</h3><div>Our final analysis encompassed 15,848 patients with diabetes and prediabetes sourced from the National Health and Nutrition Examination Survey(NHANES) spanning from 2003 to 2018. Cox proportional hazards model and restricted cubic splines (RCS) were utilized to assess the correlation between BRI and both all-cause mortality and cardiovascular mortality.</div></div><div><h3>Results</h3><div>During an average follow-up period of 92.9 months, 2655 participants (12.73 %) died, including 730 (3.44 %) from cardiovascular diseases. RCS demonstrated a U-shaped nonlinear association between BRI with all-cause mortality and cardiovascular mortality, with threshold values of 5.54 and 5.21, respectively. When BRI was below the threshold, a negative correlation was observed between BRI and all-cause mortality (HR 0.87, 95 % CI 0.81–0.93).The correlation with cardiovascular mortality is not significant. Conversely, when BRI was above the threshold, a positive correlation was observed between BRI with all-cause mortality (HR 1.10, 95 % CI 1.06–1.14) and cardiovascular mortality (HR 1.13, 95 % CI 1.07–1.20).</div></div><div><h3>Conclusion</h3><div>Our research indicates that among US adults with diabetes or prediabetes, BRI exhibits a U-shaped relationship with all-cause and cardiovascular mortality, with threshold values of 5.54 and 5.21, respectively.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"219 ","pages":"Article 111958"},"PeriodicalIF":6.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}